Oncodesign will use the proceeds from this financing to complete their growth in North-America as well as to enhance their leading position as a partner of choice for biotechnology and pharmaceutical companies to develop new anticancer drugs from discovery and preclinical stage to first clinical trials in man.
Philippe Genne, chairman and CEO of Oncodesign, said: “We are delighted to have Vizille Capital Innovation as an investor. Not only does Vizille Capital Innovation has outstanding experience in the biotechnology market, they are well-poised to significantly step up our international growth.”